Subcutaneous Biologics Market

Market Overview

Biologics currently stand out as one of the swiftly expanding categories in the pharmaceutical sector. The US Food and Drug Administration (USFDA) has greenlit over 630 biologic products to date, and more than 8,000 such drug candidates are undergoing clinical evaluations. Typically, biologic candidates are tailored for parenteral delivery, necessitating frequent administration by healthcare professionals in clinics or hospitals. However, this approach comes with drawbacks, including financial strain and time constraints, negatively impacting medical adherence. In the US alone, poor adherence to prescribed medications results in an estimated annual loss of approximately USD 188 billion. Addressing these challenges, subcutaneous drug delivery allows for patient self-medication, alleviating the need for frequent clinic or hospital visits. This approach not only enhances medical adherence but also offers advantages like effective delivery of various biologics (such as vaccines, growth hormones, and insulin) and substantial cost savings. The pharmaceutical industry is witnessing a noticeable shift in preference towards the subcutaneous route due to these benefits.

Subcutaneous Biologics Market Size

Report	Details
Market Size Value	USD 113.1 billion by 2024
Market Size Value	USD 2382.21 billion by 2032
CAGR	CAGR of 40.3%
Forecast Period	2024-2032
Base Year	2023
Historic Data	2020
Segments Covered	Biologic, Therapy, Indication, Delivery System, Distribution Channel
Geographics Covered	North America, Europe, Asia Pacific, and RoW

Major vendors in the global Subcutaneous Biologics market are Abbott Laboratories, AbbVie, Inc., Alnylam Pharmaceuticals, Bayer AG, Biogen Idec, Boston Pharmaceuticals, Bristol-Myers Squibb, Eisai, Inc., F. Hoffmann-La Roche AG, Genentech Inc., GlaxoSmithKline, Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceuticals Ltd. and Others.

Increasing Emphasis On Enhancing Patient Convenience And Adherence

A significant driver propelling the subcutaneous biologics market is the increasing emphasis on enhancing patient convenience and adherence. Traditional parenteral routes, requiring administration by healthcare professionals in clinical settings, often pose challenges related to frequent visits, financial burden, and time constraints for patients. The subcutaneous route addresses these issues by enabling self-medication, empowering patients to administer biologics at home. This shift towards patient-centric care not only improves medical adherence but also contributes to better health outcomes. The simplicity and accessibility offered by subcutaneous administration contribute significantly to the market's growth, as pharmaceutical companies and healthcare providers recognize the importance of aligning treatments with patient needs and preferences.

Market Dynamics

Drivers:

• Rising prevalence of chronic diseases
• Growing adoption of self-administration
• Advancements in technology

Opportunities:

• Development of new subcutaneous biologics for existing indications
• Development of novel delivery devices
• Development of combination therapies

Expansion into new indication0073

The expansion into new indications stands as a key strategic driver for the growth of the subcutaneous biologics market. As the understanding of subcutaneous drug delivery advances, there is a notable trend towards exploring and developing biologics for a broader range of therapeutic indications. This expansion includes venturing into diverse medical fields such as oncology, autoimmune diseases, infectious diseases, and metabolic disorders. The versatility of subcutaneous administration allows for the delivery of various biologics, including monoclonal antibodies, vaccines, and insulin, making it an attractive option for addressing a spectrum of health conditions. This strategic diversification not only broadens the market's scope but also underscores the potential of subcutaneous biologics to revolutionize treatment options across multiple medical domains, thereby fostering innovation and meeting the evolving healthcare needs of diverse patient populations.

The market for Subcutaneous Biologics is led by North America.

the global subcutaneous biologics market is categorized into four primary regions: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW). Notably, substantial healthcare expenditures are observed in countries like the United States and Canada, coupled with a high prevalence of diseases such as rheumatoid arthritis and breast cancer. The Centers for Disease Control and Prevention (CDC) project a significant rise in rheumatoid arthritis prevalence from nearly 50 million Americans in 2012 to an estimated 78 million by 2040. This autoimmune condition also impacts approximately 300,000 children in the U.S., as reported by RheumatoidArthritis.org. Within Europe, the EU-5 countries (Germany, France, United Kingdom, Italy, and Spain) emerge as a promising market due to their well-established economies. The demand for a convenient drug delivery format is also evident in developing regions like Asia Pacific and Latin America, where issues related to therapy compliance prevail. However, challenges such as a large undiagnosed population, limited access to medicines, and affordability concerns impede the growth of the subcutaneous biologics market in these developing regions.

The Lung-on-chip Segment is Anticipated to Hold the Largest Market Share During the Forecast Period

The subcutaneous drug delivery systems market is segmented into prefilled syringes, wearable injectors, auto-injectors, drug reconstitution delivery systems, and other categories. In 2022, the prefilled syringes segment emerges as the dominant player within the subcutaneous drug delivery systems sector. This prominence is attributed to the efficacy of prefilled syringes in administering biologics and drugs such as proteins, antibodies, peptides, and other large, complex molecules. The rising inclination towards self-medication and the need for high-concentration subcutaneous formulations of biologics contribute significantly to the increased demand for prefilled syringes throughout the forecast period.

Segmentations Analysis of Subcutaneous Biologics Market: -

• By Type of Biologic
  • Antibodies
  • Nucleotides
  • Proteins
  • Vaccines
  • Others
• By Type of Therapy
  • Monotherapies
  • Combination Therapies
  • Both
• By Indication
  • Cancer
  • Crohn’s disease
  • Cardiovascular disorders
  • Diabetes
  • Multiple sclerosis
  • Psoriasis
  • Rheumatoid Arthritis
  • Metabolic disorders
  • Growth hormone deficiency
  • Others
• By Delivery System
  • Prefilled syringes
  • Wearable injector
  • Automatic injector
  • Implants
  • Pen injectors
  • Others
• By Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Drug stores
  • Online pharmacies
• By Region
  • North America
    • US
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of Latin America
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
    • BENELUX
    • CIS & Russia
    • Nordics
    • Austria
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Thailand
    • Indonesia
    • Malaysia
    • Vietnam
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Nigeria
    • Egypt
    • Israel
    • Turkey
    • Rest of MEA

Recent Developments

• In November 2023, AbbVie Announced the initiation of a Phase III clinical trial of Skyrizi (risankizumab) for the treatment of non-radiographic axial spondyloarthritis
• In October 2023, Roche received FDA approval for Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the treatment of HER2-positive early breast cancer

Answers to Following Key Questions:

• What will be the Subcutaneous Biologics Market’s Trends & growth rate? What analysis has been done of the prices, sales, and volume of the top producers of Subcutaneous Biologics Market?
• What are the main forces behind worldwide Subcutaneous Biologics Market? Which companies dominate Subcutaneous Biologics Market?
• Which companies dominate Subcutaneous Biologics Market? Which business possibilities, dangers, and tactics did they embrace in the market?
• What are the global Subcutaneous Biologics industry's suppliers' opportunities and dangers in Subcutaneous Biologics Market?
• What is the Subcutaneous Biologics industry's regional sales, income, and pricing analysis? In the Subcutaneous Biologics Market, who are the distributors, traders, and resellers?
• What are the main geographic areas for various trades that are anticipated to have astounding expansion over the Subcutaneous Biologics Market?
• What are the main geographical areas for various industries that are anticipated to observe astounding expansion for Subcutaneous Biologics Market?
• What are the dominant revenue-generating regions for Subcutaneous Biologics Market, as well as regional growth trends?
• By the end of the forecast period, what will the market size and growth rate be?
• What are the main Subcutaneous Biologics Market trends that are influencing the market's expansion?
• Which key product categories dominate Subcutaneous Biologics Market? What is Subcutaneous Biologics Market’s main applications?
• In the coming years, which Subcutaneous Biologics Market technology will dominate the market?

Reason to purchase this Subcutaneous Biologics Market Report:

• Determine prospective investment areas based on a detailed trend analysis of the global Subcutaneous Biologics Market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different Subcutaneous Biologics Market segments in the top spending countries across the world and identify the opportunities each offers.
• Strengthen your understanding of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels that are driving the global Subcutaneous Biologics Market , providing a clear picture of future opportunities that can be tapped, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs that are being undertaken by the different countries within the global Subcutaneous Biologics Market.
• Make correct business decisions based on a thorough analysis of the total competitive landscape of the sector with detailed profiles of the top Subcutaneous Biologics Market providers worldwide, including information about their products, alliances, recent contract wins, and financial analysis wherever available.